Guy Griebel

List of Publications by Year in Descending Order

138 papers	11,459 citations	56 h-index	105 g-index
166 ext. papers	12,259 ext. citations	5.7 avg, IF	6.15 L-index

#	Paper	IF	Citations
138	The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents. *Scientific Reports*, **2019**, 9, 18045	4.9	36
137	The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents. *Scientific Reports*, **2018**, 8, 2416	4.9	42
136	Creativity in large pharmaceutical research organizations: unleash the hungry drug hunter. *British Journal of Pharmacology*, **2017**, 174, 2152-2153	8.6	4
135	The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia. *Scientific Reports*, **2016**, 6, 35320	4.9	29
134	Long-lasting memory abnormalities following exposure to the mouse defense test battery: An animal model of PTSD. *Physiology and Behavior*, **2015**, 146, 67-72	3.5	2
133	The CRF1 receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: comparison with paroxetine and d-cycloserine. *Behavioural Brain Research*, **2015**, 279, 41-6	3.4	9
132	Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents. *Scientific Reports*, **2015**, 5, 7642	4.9	75
131	Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins. *Current Pharmaceutical Design*, **2015**, 21, 3807-12	3.3	5
130	CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents. *Psychopharmacology*, **2014**, 231, 1289-303	4.7	2
129	Optogenetics to study the circuits of fear- and depression-like behaviors: a critical analysis. *Pharmacology Biochemistry and Behavior*, **2014**, 122, 144-57	3.9	45
128	Mood and Anxiety Disorders. *Methods and Principles in Medicinal Chemistry*, **2014**, 193-206	0.4	
127	Mice deficient in cryptochrome 1 (cry1 (-/-)) exhibit resistance to obesity induced by a high-fat diet. *Frontiers in Endocrinology*, **2014**, 5, 49	5.7	31
126	The CRF1 receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: comparison with paroxetine and D-cycloserine. *Psychopharmacology*, **2013**, 228, 97-107	4.7	17
125	50 years of hurdles and hope in anxiolytic drug discovery. *Nature Reviews Drug Discovery*, **2013**, 12, 667-87	64.1	259
124	Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 6141-5	2.9	4
123	Further evidence for the sleep-promoting effects of 5-HT7A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats. *Neuropharmacology*, **2013**, 70, 19-26	5.5	14
122	Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2013**, 40, 213-20	5.5	32

121	Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats: a putative model of the negative symptoms of schizophrenia?. *Behavioural Pharmacology*, **2013**, 24, 543-51	2.4	23
120	SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. *Pharmacology Biochemistry and Behavior*, **2012**, 102, 203-14	3.9	36
119	The CRF receptor antagonist SSR125543 attenuates long-term cognitive deficit induced by acute inescapable stress in mice, independently from the hypothalamic pituitary adrenal axis. *Pharmacology Biochemistry and Behavior*, **2012**, 102, 415-22	3.9	17
118	Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?. *Pharmacology & Therapeutics*, **2012**, 133, 116-23	13.9	20
117	Awakening properties of newly discovered highly selective H receptor antagonists in rats. *Behavioural Brain Research*, **2012**, 232, 416-20	3.4	13
116	Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?. *Nature Reviews Drug Discovery*, **2012**, 11, 462-78	64.1	144
115	The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. *Journal of Clinical Psychiatry*, **2012**, 73, 1403-11	4.6	56
114	Acute inescapable stress exposure induces long-term sleep disturbances and avoidance behavior: a mouse model of post-traumatic stress disorder (PTSD). *Behavioural Brain Research*, **2011**, 221, 149-54	3.4	41
113	Antidepressants recruit new neurons to improve stress response regulation. *Molecular Psychiatry*, **2011**, 16, 1177-88	15.1	347
112	SSR181507, a dopamine D receptor and 5-HT(A) receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities. *Pharmacology Biochemistry and Behavior*, **2011**, 97, 428-35	3.9	8
111	The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition. *Pharmacology Biochemistry and Behavior*, **2011**, 98, 405-11	3.9	7
110	The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice. *Pharmacology Biochemistry and Behavior*, **2011**, 98, 425-31	3.9	23
109	AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. *Psychopharmacology*, **2011**, 215, 149-63	4.7	30
108	Risk assessment as an evolved threat detection and analysis process. *Neuroscience and Biobehavioral Reviews*, **2011**, 35, 991-8	9	243
107	The Mouse Defense Test Battery: A Model Measuring Different Facets of Anxiety-Related Behaviors. *Neuromethods*, **2011**, 97-106	0.4	4
106	The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. *Neuropsychopharmacology*, **2010**, 35, 416-27	8.7	36
105	Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test battery. *Neuroscience Letters*, **2010**, 485, 241-5	3.3	3
104	Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress. *Behavioural Brain Research*, **2010**, 206, 310-2	3.4	24

103	Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. *Pharmacology Biochemistry and Behavior*, **2010**, 96, 206-10	3.9	16
102	Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. *Neuropsychopharmacology*, **2009**, 34, 1753-63	8.7	51
101	Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. *Neuropsychopharmacology*, **2009**, 34, 1363-80	8.7	149
100	Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. *Psychopharmacology*, **2009**, 202, 385-96	4.7	67
99	Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. *Pharmacology Biochemistry and Behavior*, **2008**, 89, 36-45	3.9	48
98	Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression. *Pharmacology Biochemistry and Behavior*, **2008**, 89, 623-6	3.9	42
97	Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. *Pharmacology Biochemistry and Behavior*, **2008**, 91, 47-58	3.9	81
96	Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. *Biological Psychiatry*, **2008**, 64, 293-301	7.9	413
95	Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. *Neuropsychopharmacology*, **2008**, 33, 574-87	8.7	84
94	Chapter 1.1 Introduction to the handbook on fear and anxiety. *Handbook of Behavioral Neuroscience*, **2008**, 17, 3-7	0.7	3
93	Chapter 4.6 Genetic factors underlying anxiety-behavior: A meta-analysis of rodent studies involving targeted mutations of neurotransmission genes. *Handbook of Behavioral Neuroscience*, **2008**, 17, 325-354	0.7	0
92	Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling. *Psychopharmacology*, **2007**, 194, 161-71	4.7	37
91	SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. *Neuropsychopharmacology*, **2007**, 32, 1-16	8.7	165
90	SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. *Neuropsychopharmacology*, **2007**, 32, 17-34	8.7	228
89	Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats. *Psychopharmacology*, **2006**, 187, 237-44	4.7	68
88	Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. *Pharmacology Biochemistry and Behavior*, **2006**, 83, 533-9	3.9	57
87	Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat. *Neuropsychopharmacology*, **2006**, 31, 2180-7	8.7	37
86	Long-term impaired memory following predatory stress in mice. *Physiology and Behavior*, **2006**, 87, 45-50	3.5	27

85	Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders. *CNS and Neurological Disorders - Drug Targets*, **2006**, 5, 135-45	2.6	36
84	Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. *Biological Psychiatry*, **2005**, 57, 261-7	7.9	217
83	Defensive responses to predator threat in the rat and mouse. *Current Protocols in Neuroscience*, **2005**, Chapter 8, Unit 8.19	2.7	34
82	Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). *Neuropsychopharmacology*, **2005**, 30, 145-55	8.7	214
81	An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. *CNS Neuroscience & Therapeutics*, **2005**, 11, 53-68		56
80	AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters. *Pharmacology Biochemistry and Behavior*, **2005**, 80, 189-94	3.9	78
79	CB1 receptor antagonists for the treatment of nicotine addiction. *Pharmacology Biochemistry and Behavior*, **2005**, 81, 387-95	3.9	113
78	Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat. *Pharmacology Biochemistry and Behavior*, **2005**, 82, 223-7	3.9	51
77	SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. *Psychopharmacology*, **2005**, 181, 134-44	4.7	45
76	Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. *Current Pharmaceutical Design*, **2005**, 11, 1549-59	3.3	78
75	Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415. *Neuropsychopharmacology*, **2005**, 30, 35-42	8.7	99
74	Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs. *Neuropsychopharmacology*, **2005**, 30, 1996-2005	8.7	41
73	Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one]. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 313, 1118-25	4.7	39
72	Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. *Neuropsychopharmacology*, **2005**, 30, 1963-85	8.7	194
71	Nonpeptide vasopressin V1b receptor antagonists. *Handbook of Behavioral Neuroscience*, **2005**, 15, 409-421		
70	Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. *Molecular Psychiatry*, **2004**, 9, 278-86, 224	15.1	260
69	Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters. *Pharmacology Biochemistry and Behavior*, **2004**, 77, 465-9	3.9	33
68	Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. *European Journal of Pharmacology*, **2004**, 497, 49-53	5.3	93

67	Response to Roesler et al.: Neuropeptides and stress-related disorders multiple targets and converging concepts. *Trends in Pharmacological Sciences*, **2004**, 25, 242-243	13.2	3
66	Impaired memory following predatory stress in mice is improved by fluoxetine. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2004**, 28, 123-8	5.5	18
65	SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. *Neuropharmacology*, **2004**, 46, 1121-9	5.5	52
64	The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic. *European Journal of Pharmacology*, **2003**, 463, 97-116	5.3	193
63	SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. *CNS Neuroscience & Therapeutics*, **2003**, 9, 3-20		62
62	Conditioning and residual emotionality effects of predator stimuli: some reflections on stress and emotion. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2003**, 27, 1177-85	5.5	150
61	Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. *Trends in Pharmacological Sciences*, **2003**, 24, 580-8	13.2	335
60	Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2003**, 27, 625-31	5.5	175
59	Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals. *Stress*, **2003**, 6, 199-206	3	85
58	The vasopressin V1b receptor as a therapeutic target in stress-related disorders. *CNS and Neurological Disorders*, **2003**, 2, 191-200		60
57	Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 300, 1122-30	4.7	201
56	Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 6370-5	11.5	407
55	SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-meth a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 303, 1180-8	4.7	39
54	4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)- 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 301, 333-45	4.7	220
53	4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)- hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 301, 322-32	4.7	81
52	Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents. *Psychopharmacology*, **2001**, 158, 241-51	4.7	47
51	Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. *Neuroscience and Biobehavioral Reviews*, **2001**, 25, 205-18	9	339
50	Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery. *Neuroscience and Biobehavioral Reviews*, **2001**, 25, 619-26	9	30

49	Measuring normal and pathological anxiety-like behaviour in mice: a review. *Behavioural Brain Research*, **2001**, 125, 141-9	3.4	651
48	Behavioral and neurochemical changes following predatory stress in mice. *Neuropharmacology*, **2001**, 41, 400-8	5.5	122
47	Beta-CCT, a selective BZ-omega1 receptor antagonist, blocks the anti-anxiety but not the amnesic action of chlordiazepoxide in mice. *Behavioural Pharmacology*, **2000**, 11, 125-31	2.4	32
46	Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. *Psychopharmacology*, **2000**, 148, 164-70	4.7	339
45	The effects of compounds varying in selectivity as 5-HT(1A) receptor antagonists in three rat models of anxiety. *Neuropharmacology*, **2000**, 39, 1848-57	5.5	68
44	Subtype-selective benzodiazepine receptor ligands **2000**, 77-94		1
43	Comparison of the pharmacological properties of classical and novel BZ-omega receptor ligands. *Behavioural Pharmacology*, **1999**, 10, 483-95	2.4	37
42	Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT(1A) receptor antagonists. *Psychopharmacology*, **1999**, 144, 121-30	4.7	48
41	New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes. *Psychopharmacology*, **1999**, 146, 205-13	4.7	71
40	Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? **1999**, 82, 1-61		140
39	Orphanin FQ, a novel neuropeptide with anti-stress-like activity. *Brain Research*, **1999**, 836, 221-4	3.7	91
38	Differences in anxiolytic-like profile of two novel nonbenzodiazepine BZ (omega) receptor agonists on defensive behaviors of mice. *Pharmacology Biochemistry and Behavior*, **1999**, 62, 689-94	3.9	17
37	Discriminative stimulus effects of drugs acting at GABA(A) receptors: differential profiles and receptor selectivity. *Pharmacology Biochemistry and Behavior*, **1999**, 64, 269-73	3.9	27
36	Study of the modulatory activity of BZ (omega) receptor ligands on defensive behaviors in mice: evaluation of the importance of intrinsic efficacy and receptor subtype selectivity. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **1999**, 23, 81-98	5.5	9
35	Pharmacological studies on synthetic flavonoids: comparison with diazepam. *Neuropharmacology*, **1999**, 38, 965-77	5.5	53
34	Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats. *Physiology and Behavior*, **1999**, 67, 315-20	3.5	72
33	Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. *Psychopharmacology*, **1998**, 138, 55-66	4.7	183
32	Benzodiazepine and serotonergic modulation of antipredator and conspecific defense. *Neuroscience and Biobehavioral Reviews*, **1998**, 22, 597-612	9	66

31	Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels. *Neuropharmacology*, **1998**, 37, 927-35	5.5	54
30	Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents. *Journal of Psychopharmacology*, **1998**, 12, 356-65	4.6	31
29	CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours. *Behavioural Pharmacology*, **1997**, 8, 549-60	2.4	41
28	A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. *Neuropharmacology*, **1997**, 36, 793-802	5.5	109
27	Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. *Neuroscience and Biobehavioral Reviews*, **1997**, 21, 783-9	9	182
26	Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. *Pharmacology Biochemistry and Behavior*, **1997**, 57, 817-27	3.9	150
25	An ethopharmacological analysis of selective activation of 5-HT1A receptors: the mouse 5-HT1A syndrome. *Pharmacology Biochemistry and Behavior*, **1997**, 57, 897-908	3.9	46
24	Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. *Psychopharmacology*, **1997**, 131, 180-6	4.7	27
23	Genetic differences in the mouse defense test battery. *Aggressive Behavior*, **1997**, 23, 19-31	2.8	45
22	Predator-elicited flight responses in Swiss-Webster mice: an experimental model of panic attacks. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **1996**, 20, 185-205	5.5	50
21	Further evidence for differences between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands in murine models of "state" and "trait" anxiety. *Neuropharmacology*, **1996**, 35, 1081-91	5.5	34
20	Evidence that the behaviors in the Mouse Defense Test Battery relate to different emotional states: a factor analytic study. *Physiology and Behavior*, **1996**, 60, 1255-60	3.5	54
19	Preclinical profile of the mixed 5-HT1A/5-HT2A receptor antagonist S 21,357. *Pharmacology Biochemistry and Behavior*, **1996**, 54, 509-16	3.9	15
18	Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. *Psychopharmacology*, **1995**, 120, 57-66	4.7	94
17	5-HT1A agonists modulate mouse antipredator defensive behavior differently from the 5-HT2A antagonist pirenperone. *Pharmacology Biochemistry and Behavior*, **1995**, 51, 235-44	3.9	44
16	5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research **1995**, 65, 319-95		374
15	Gender bias in the preclinical psychopharmacology of anxiety: male models for (predominantly) female disorders. *Journal of Psychopharmacology*, **1995**, 9, 79-82	4.6	61
14	Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam. *Neuropharmacology*, **1995**, 34, 1625-33	5.5	86

13	Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. *Psychopharmacology*, **1994**, 113, 463-70	4.7	110
12	Evidence that tolerance to the anxiogenic-like effects of mCPP does not involve alteration in the function of 5-HT(2C) receptors in the rat choroid plexus. *Behavioural Pharmacology*, **1994**, 5, 642-645	2.4	10
11	Some critical determinants of the behaviour of rats in the elevated plus-maze. *Behavioural Processes*, **1993**, 29, 37-47	1.6	93
10	Anxiolytic-like effects of a selective 5-HT1A agonist, S20244, and its enantiomers in mice. *NeuroReport*, **1992**, 3, 84-6	1.7	35
9	Prolactin similar to ectopic pituitary isograft restores responsiveness in Snell dwarf mice. *NeuroReport*, **1992**, 3, 210-2	1.7	2
8	Behavioral profile of the 5HT1A receptor antagonist (S)-UH-301 in rodents and monkeys. *Brain Research Bulletin*, **1992**, 29, 901-4	3.9	57
7	m-Chlorophenylpiperazine enhances neophobic and anxious behaviour in mice. *NeuroReport*, **1991**, 2, 627-9	1.7	35
6	Behavioural effects of selective A2 adenosine receptor antagonists, CGS 21197 and CGS 22706, in mice. *NeuroReport*, **1991**, 2, 139-40	1.7	15
5	Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors. *Pharmacology Biochemistry and Behavior*, **1991**, 39, 321-3	3.9	35
4	Comparison of the behavioural effects of an adenosine A1/A2-receptor antagonist, CGS 15943A, and an A1-selective antagonist, DPCPX. *Psychopharmacology*, **1991**, 103, 541-4	4.7	57
3	Anxiolytic and sedative effects of 5-HT1A ligands, 8-OH-DPAT and MDL 73005EF, in mice. *NeuroReport*, **1990**, 1, 267-70	1.7	26
2	Serenics fluprazine (DU 27716) and eltoprazine (DU 28853) enhance neophobic and emotional behaviour in mice. *Psychopharmacology*, **1990**, 102, 498-502	4.7	21
1	The Mouse Defense Test Battery: An experimental model of different emotional states.75-85		4